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MaBACKGROUND Mortality in cardiogenic shock (CS) remains high. Early risk stratiﬁcation is crucial to make adequate
treatment decisions.
OBJECTIVES This study sought to develop an easy-to-use, readily available risk prediction score for short-term
mortality in patients with CS, derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.
METHODS The score was developed using a stepwise multivariable regression analysis.
RESULTS Six variables emerged as independent predictors for 30-day mortality and were used as score parameters:
age >73 years, prior stroke, glucose at admission >10.6 mmol/l (191 mg/dl), creatinine at admission >132.6 mmol/l
(1.5 mg/dl), Thrombolysis In Myocardial Infarction ﬂow grade <3 after percutaneous coronary intervention, and arterial
blood lactate at admission >5 mmol/l. Either 1 or 2 points were attributed to each variable, leading to a score in 3 risk
categories: low (0 to 2), intermediate (3 or 4), and high (5 to 9). The observed 30-day mortality rates were 23.8%,
49.2%, and 76.6%, respectively (p < 0.0001). Validation in the IABP-SHOCK II registry population showed good
discrimination with an area under the curve of 0.79. External validation in the CardShock trial population (n ¼ 137)
showed short-term mortality rates of 28.0% (score 0 to 2), 42.9% (score 3 to 4), and 77.3% (score 5 to 9; p < 0.001)
and an area under the curve of 0.73. Kaplan-Meier analysis revealed a stepwise increase in mortality between the
different score categories (0 to 2 vs. 3 to 4: p ¼ 0.04; 0 to 2 vs. 5 to 9: p ¼ 0.008).
CONCLUSIONS The IABP-SHOCK II risk score can be easily calculated in daily clinical practice and strongly
correlated with mortality in patients with infarct-related CS. It may help stratify patient risk for short-term mortality
and might, thus, facilitate clinical decision making. (Intraaortic Balloon Pump in Cardiogenic Shock II [IABP-SHOCK II];
NCT00491036) (J Am Coll Cardiol 2017;69:1913–20) © 2017 by the American College of Cardiology Foundation.C ardiogenic shock (CS) is the most commoncause of in-hospital death in patients withacute myocardial infarction (AMI) (1).
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ABBR EV I A T I ON S
AND ACRONYMS
AMI = acute myocardial
infarction
AUC = area under the curve
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
CS = cardiogenic shock
GFR = glomerular ﬁltration
rate
HR = hazard ratio
IABP = intra-aortic balloon
pump
PCI = percutaneous coronary
intervention
ROC = receiver-operating
characteristic
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1914therapies, such as active assist devices).
Therefore, there remains an obvious need
for a risk stratiﬁcation tool that is simple,
easily applicable in clinical practice, and
readily available directly after admission at
the catheterization laboratory. Furthermore,
designing clinical trials in patients with CS
is challenging due to the large heterogeneity
and variability of outcomes in this popula-
tion of critically ill patients (3). A severity
scoring system might be useful to conduct
trials with a more homogeneous patient
population.
Until now, few studies of risk stratiﬁcation
in CS have been performed. Most of these,
such as a post hoc analysis from the
TRIUMPH (Tilarginine Acetate Injection in a
Randomized International Study in UnstableMI Patients With Cardiogenic Shock) trial, only iden-
tiﬁed and described predictors for worse outcome,
without proposing a risk-scoring model (4–6).
Although several scores have been developed based
on patient registry data and randomized clinical trials
(7–10), almost all of them share certain limitations: 1)
they were not validated; 2) they were derived from
small studies; 3) the etiology of CS often was not
restricted to AMI; and 4) the parameters used cannot
be easily assessed directly in the catheterization lab.
Furthermore, some of the underlying studies were
performed decades ago and included AMI patients
without coronary revascularization. Consequently,
potentially relevant variables relating to the revas-
cularization procedure, such as procedural success as
assessed by Thrombolysis In Myocardial Infarction
ﬂow grade were not included in these analyses and
scores.SEE PAGE 1921The aim of this study was to develop a simple,
easy-to-use, readily available, fully validated risk
score for short-term mortality prediction in the
catheterization laboratory in patients with AMI-
related CS undergoing PCI enrolled in the largest
randomized CS trial to date.
METHODS
The present analysis is a substudy of the randomized
IABP-SHOCK II (Intraaortic Balloon Pump in Cardio-
genic Shock II) trial. In this trial, intra-aortic balloon
pump (IABP) support was compared with no IABP
support in patients with AMI-related CS. There were
no signiﬁcant differences between the 2 treatment
groups with respect to short- and long-term out-
comes. The design of the trial and its main resultshave been published previously (11–13). Brieﬂy, 600
patients were enrolled in 37 centers in Germany and
randomly allocated to either IABP support or to a
control group in a 1:1 fashion. CS was deﬁned as
hypotension, pulmonary congestion, and signs of
end-organ hypoperfusion. Exclusion criteria were
duration of CS >12 h, cardiopulmonary resuscitation
>30 min, severe cerebral deﬁcit, mechanical causes of
CS, age >90 years, absolute contraindications against
IABP insertion, shock of other cause, or severe
concomitant disease with life expectancy <6 months.
All patients underwent cardiac catheterization
immediately after hospital admission. The primary
endpoint was 30-day all-cause mortality. Patients
with AMI complicated by CS who met any exclusion
criterion of the IABP-SHOCK II trial were enrolled into
an associated registry (n ¼ 188). The study, which was
conducted according to the Declaration of Helsinki,
was approved by the local ethics committees and all
patients or their legal representatives gave written
informed consent.
STATISTICAL ANALYSIS. The model was developed
on the randomized population of the IABP-SHOCK II
trial (n ¼ 600) using a stepwise multivariable Cox
proportional hazards regression analysis with the for-
ward selection technique. Unselected extensive uni-
variable testing was performed including all database
variables potentially associated with mortality. Vari-
ables signiﬁcantly related to mortality in univariable
testing (p < 0.10) were further examined in multivari-
able analysis. Herein, 6 variables remained statistically
signiﬁcant associated with mortality. These variables
constitute the score parameters. Only patients with
complete datasets for these 6 score candidate variables
were considered for further testing. Patients treated
conservatively (19 of 600; 3.2%), as well as patients
undergoing immediate coronary artery bypass grafting
(CABG) (6 of 600; 1%), were excluded from the present
analysis. In 17 of 600 (2.8%) patients, CABG was
performed after PCI. Of these, 4 patients had to be
excluded due to missing parameters. The remaining 13
patients were included in the analysis.
Continuous variables were dichotomized. The
optimal cutoff points were deﬁned using the Youden
index. The scoring system was determined by
rounding the respective parameter estimates, attrib-
uting either 1 or 2 points to each variable, based on
the observed hazard ratio (HR). Parameters with a
rounded HR of 2 or more were assigned 2 points;
those with a rounded HR below 2 were assigned 1
point. According to the score, the population was
classiﬁed into 3 risk categories: low (0 to 2), inter-
mediate (3 or 4), and high (5 to 9). Comparison of
FIGURE 1 Flow Chart of the Development and Validation Cohorts
IABP-SHOCK II study
(n=600)
IABP-SHOCK II registry
(n=188)
CardShock study
(n=219)
CardShock study
Validation cohort
(n=137)
Non-ACS etiology
(n=42)
ACS etiology; no PPCI
(n=33)
Missing data (n=7)
IABP-SHOCK II registry
Validation cohort
(n=98)
Development
Validation
Developmental cohort
(n=480)
Missing data (n=120)
Missing values:
Glucose*: 74
Creatinine*: 13
Lactate*: 23
TIMI-flow post PCI: 26
Missing data (n=90)
Missing values:
Glucose*: 64
Creatinine*: 20
Lactate*: 21
TIMI-flow post PCI: 33
Prior stroke: 5
The development cohort comprised patients from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial whereas the
validation cohorts were from the IABP-SHOCK II registry and CardShock trial. In the IABP-SHOCK II trial and registry, patients with missing
data with respect to the score variables were excluded. With respect to the CardShock trial cohort, only patients with cardiogenic shock due to
acute coronary syndrome (ACS) undergoing primary percutaneous coronary intervention (PPCI) were included. *At admission.
TIMI ¼ Thrombolysis In Myocardial Infarction.
J A C C V O L . 6 9 , N O . 1 5 , 2 0 1 7 Pöss et al.
A P R I L 1 8 , 2 0 1 7 : 1 9 1 3 – 2 0 The IABP-SHOCK II Risk Score
191530-day mortality rates was done by chi-square testing
and by Kaplan-Meier analysis with pairwise log-rank
testing. Receiver-operating characteristic (ROC)
analysis was performed to assess discriminative po-
wer. Calibration of the score was assessed in the 2
validation cohorts by dividing the sample into 5 equal
groups based on the predicted probability, then
plotting the mean probability of each quintile against
the observed frequency of 30-day mortality for that
group.
Patients included in the IABP-SHOCK II registry
served as an internal validation cohort. External
validation was performed in the subset of patients
with infarction-related CS who underwent PCI
enrolled in a European multicenter study (CardShock
[NCT01374867] trial) (10). Comparison of 30-day
mortality rates in the 2 validation cohorts, according
to the different score categories, was done by chi-
square testing as well as by Kaplan-Meier analysis
with pairwise log-rank testing. Furthermore, ROC
analysis was performed to assess the discriminative
power of the score. All statistical analyses were per-
formed using SAS for Windows version 9.3 (SAS
Institute, Cary, North Carolina) by an independentstatistician at the Institut für Herzinfarktforschung,
Ludwigshafen, Germany.
RESULTS
Of the 600 patients enrolled in the trial, only 480
patients with complete datasets for the selected 6
variables were included as the ﬁnal cohort (Figure 1).
Thirty-day mortality rates did not differ between the
cohorts of included and excluded patients (40.4%
and 42.0%, respectively; p ¼ 0.75). Per the baseline
characteristics of these patients (Table 1), 69% were
men and mean age was 70 years. All patients had
infarct-related CS with the classical cardiovascular
risk factors; for example, nearly three-quarters had
arterial hypertension and >42% had dyslipidemia. In
addition, they were characterized by several comor-
bidities, such as peripheral arterial disease or renal
insufﬁciency. Of the 480 patients, 194 (40.6%) died
within 30 days.
VARIABLE IDENTIFICATIONAND SCORE CREATION. After
multivariable testing, the following 6 variables
remained statistically signiﬁcant predictors and were
included in the model: age, history of stroke, glucose
TABLE 1 Baseline Characteristics
IABP-SHOCK II Trial
Development
Cohort (n ¼ 480)
IABP-SHOCK II
Registry Validation
Cohort (n ¼ 98)
CardShock Trial
Validation Cohort
(n ¼ 137)
Demographic data
Age, yrs 70 (58–77) 71 (59–76) 68 (61–76)
Male 331/480 (69) 75/98 (73.5) 106/137 (77.4)
Height, cm 174 (167–180) 175 (168–180) 171 (165–176)
Weight, kg 80 (73–90) 85 (75–94) 78 (70–85)
BMI, kg/m2 27.3 (24.7–30.0) 27.2 (24.8–31.1) 26.8 (24.2–26.5)
Systolic blood pressure, mm Hg 90 (80–109) 105 (81–121) 85 (74–96)
Diastolic blood pressure, mm Hg 58 (48–68) 60 (47.5–76) 51 (43–60)
Mechanical ventilation 270/480 (56.3) 52/98 (53.1) 81/137 (59.1)
Cardiopulmonary resuscitation 209/480 (43.5) 49/98 (50) 39/137 (28.5)
Cardiovascular risk factors/cardiovascular diseases
Smoking 165/475 (34.7) 33/95 (34.7) 58/137 (42.3)
Arterial hypertension 341/477 (71.5) 66/96 (68.8) 81/137 (59.1)
Dyslipidemia 201/476 (42.2) 27/96 (28.1) 64/137 (46.7)
Diabetes mellitus 162/478 (33.9) 40/96 (41.7) 39/137 (28.5)
History of myocardial infarction 109/480 (22.7) 15/98 (15.3) 31/137 (22.6)
History of stroke 39/480 (8.1) 5/98 (5.1) 12/137 (8.8)
Known peripheral artery disease 62/480 (12.9) 18/98 (18.4) 14/137 (10.2)
Prior PCI 99/479 (20.7) 14/98 (14.3) 20/137 (14.6)
Prior CABG 26/480 (5.4) 10/98 (10.2) 6/137 (4.4)
Laboratory results
Baseline serum creatinine
mmol/l 114.0 (92.5–146.0) 129.1 (95.5–171.0) 119.7 (78.5–101.0)
mg/dl 1.3 (1.1–1.7) 1.5 (1.1–1.9) 1.4 (0.9–1.1)
Baseline glucose
mmol/l 11.6 (8.1–16.8) 10.9 (8.0–17.6) 13.6 (8.3–18.1)
mg/dl 209 (146–303) 196 (144–317) 245 (150–326)
Baseline arterial lactate, mmol/l 3.7 (2.1–7.3) 3.8 (1.7–7.7) 4.3 (1.8–5.2)
Catheterization lab data
Primary PCI 480/480 (100) 98/98 (100) 137/137 (100)
TIMI ﬂow grade 3 after PCI 395/480 (82.3) 80/98 (81.6) 98/137 (71.5)
Values are mean (interquartile range) or n/N (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; IABP-SHOCK ¼ Intraaortic Balloon Pump in
Cardiogenic Shock; PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 2 Results of Multivariable Cox Regression Analysis
Hazard Ratio
(95% CI)
Parameter
Estimate p Value
Age >73 yrs 1.54 (1.16–2.05) 0.43 0.003
History of stroke 2.09 (1.39–3.15) 0.73 0.0004
Glucose >10.6 mmol/l
(191 mg/dl)*
1.48 (1.10–2.01) 0.39 0.01
Creatinine >132.6 mmol/l
(1.5 mg/dl)*
1.57 (1.17–2.11) 0.44 0.003
Arterial lactate >5 mmol/l* 1.98 (1.47–2.66) 0.68 <0.0001
TIMI ﬂow grade <3 after PCI 2.73 (1.11–6.73) 0.72 0.03
*At admission.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1916at admission, creatinine at admission, arterial blood
lactate at admission, and TIMI ﬂow grade <3 after
PCI. The results of the regression analysis are shown
in Table 2. The cutoff points were determined by the
Youden index as follows: age >73 years, glucose at
admission >10.6 mmol/l (191 mg/dl), creatinine at
admission >132.6 mmol/l (1.5 mg/dl), and arterial
lactate at admission >5 mmol/l. Subsequently, the
IABP-SHOCK II score was created attributing either 1
or 2 points to the variables (Central Illustration). The
score has a minimum of 0 and a maximum of 9 points.
Using the score, the population was classiﬁed into 3
risk categories: low (0 to 2), intermediate (3 or 4), and
high (5 to 9), as shown in the Central Illustration. Of
480 patients, 235 (49.0%) were at low risk, 181 (37.7%)
were at intermediate risk, and 64 (13.3%) were at
high risk.We repeated the analysis by entering the laboratory
results (lactate, creatinine, and glucose) as well as age
as continuous variables. In this analysis, there was no
difference compared to the analysis with dichoto-
mized variables. The parameters remaining signiﬁcant
after multivariable testing were the same as in the ﬁrst
analysis. Expectedly, the HRs were slightly lower
when variables were entered as continuous variables.
Notably, the attribution of 1 or 2 points according to
the rounded HR (i.e., 2 points for parameters with a
rounded HR of $2 and 1 point for parameters with an
HR <2) for determination of the scoring system also
remained unchanged.
Per the score risk categories of low, intermediate,
and high, the observed mortality rates assessed by
chi-square testing were 23.8%, 49.2%, and 76.6%,
respectively (p < 0.0001). The Central Illustration
depicts the Kaplan-Meier curves for 30-day mortal-
ity according to the 3 score categories. In c-statistics,
the predictive value of the score with respect to
30-day mortality was good with an area under the
curve (AUC) of 0.74 (95% conﬁdence interval [CI]:
0.69 to 0.78).
INTERNAL AND EXTERNAL VALIDATION. Of the 188
patients included in the registry, complete data were
available for 98 patients, who served as the ﬁrst
validation cohort. Of these patients, 45 (45.9%) were
low risk, 39 (39.8%) were intermediate risk, and 14
(14.3%) were high risk. Once again, event rates of
the excluded patients were comparable to the
included patients (54.8% vs. 53.6%, respectively;
p ¼ 0.88). Overall 30-day mortality was 53.1%. In
addition, the data of 137 patients with infarction-
related CS who underwent primary PCI included in
the multicenter, observational CardShock trial were
used for external validation. Of these patients
81 (59%) were low risk, 35 (26%) were intermediate
risk, and 21 (15%) were high risk. Of the 137 patients,
55 (40.1%) died.
CENTRAL ILLUSTRATION Cardiogenic Shock Complicating Acute Myocardial Infarction:
IABP-SHOCK II Risk Score
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Pöss, J. et al. J Am Coll Cardiol. 2017;69(15):1913–20.
Using a stepwise multivariable regression analysis, we sought to create a risk score for mortality in patients with cardiogenic shock
complicating acute myocardial infarction. The scoring system was determined by rounding the respective parameter estimates, attributing
either 1 or 2 points to each variable, based on the observed hazard ratio, and the total score separated by risk category: low: 0 to 2 points;
intermediate: 3 or 4 points; and high: 5 to 9 points. In total, 480 patients included in the development population were classiﬁed according
to the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) risk score into the low-risk (n ¼ 235; 49.0%), intermediate-risk (n ¼
181; 37.7%), or high-risk (n ¼ 64; 13.3%) categories. The Kaplan-Meier analysis for 30-day mortality showed a highly signiﬁcant, stepwise
increase in mortality. *At admission. PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1917In the validation analysis performed in the IABP-
SHOCK II registry patients, c-statistics showed good
discrimination, with an AUC of 0.79 (95% CI: 0.70 to
0.88). Comparison of the predicted probabilities with
the observed frequencies of 30-day mortality ac-
cording either to score quintiles or to the 3 categories
demonstrated good calibration of the score (Figure 2).
The observed mortality rates (low vs. intermediate vs.
high) in chi-square testing were 31.1%, 63.2%, and
100%, respectively (p < 0.0001) (Figure 3A).
External validation in the CardShock cohort
showed similar results with 30-day mortality rates of
28.0% (low), 42.9% (intermediate), and 77.3% (high;
p < 0.001) and an AUC of 0.73 (95% CI: 0.64 to 0.81).
Figure 3B depicts the Kaplan-Meier curves with pair-
wise comparisons by log-rank test (score 0 to 2 vs. score
3 or 4: p ¼ 0.04; score 0 to 2 vs. score 5 to 9: p ¼ 0.008).DISCUSSION
There are 4 major strengths of the proposed IABP-
SHOCK II score. First, the large, homogeneous popu-
lation of patients with AMI-related CS undergoing
early revascularization was from the largest,
contemporary randomized clinical trial in this setting.
Second, it was based on simple, dichotomized vari-
ables and thus can be rapidly and easily calculated in
clinical routine. Third, it included variables that are
readily available directly in the catheterization labo-
ratory after hospital admission and does not require
elaborate assessment of variables. Fourth, it has been
validated in the IABP-SHOCK II registry as well as in
an external CS cohort.
As CS is known to have unacceptably high and
variable mortality rates, early risk stratiﬁcation of the
FIGURE 2 IABP-SHOCK II Registry Validation Cohort Calibration Curve
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Calibration of the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) score
was assessed by dividing the IABP-SHOCK II registry cohort (n ¼ 98) into 5 equal groups
per the predicted probability of 30-day mortality. Subsequently, the mean probability of
predicted 30-day mortality of each quintile was plotted against the observed frequency
of mortality. The ﬁrst number denotes the predicted probability; the second number
denotes the observed 30-day mortality.
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1918patients is a crucial clinical task, which remains
challenging in the acute setting (14). Many studies
aimed to identify predictors for adverse outcome, but
only a few studies have proposed a risk score. In a
monocentric trial including 74 patients with ST-
segment elevation myocardial infarction and CS, age
>75 years, left main coronary artery occlusion, left
ventricular ejection fraction <25%, and post-
procedural TIMI ﬂow grade <3 were signiﬁcantly
associated with dismal prognosis (15). A score based
on these 4 variables predicted 1-year survival. Other
scores were developed based on data of patients
included in registries and clinical trials, such as the
ACC-NCDR (American College of Cardiology-National
Cardiovascular Data Registry) registry (7), GUSTO-I
(Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries)
trial (8), and the SHOCK (SHould we emergently
revascularize Occluded Coronaries for cardiogenic
shock) trial and registry (9). Harjola et al. (10) devel-
oped a risk score based on patients with CS in
the CardShock study. This model included age >75
years, confusion at presentation, previous AMI or
CABG, acute coronary syndrome etiology, reduced left
ventricular ejection fraction, arterial blood lactate,
and estimated glomerular ﬁltration rate (GFR).
However, these available scoring systems have
several limitations. Some of them, such as the score
proposed by Garcia-Alvarez et al. (15), are based onvery small trials. Another major point of criticism:
some scores were developed based on clinical trials
performed in the pre-PCI era, thus including patients
either undergoing ﬁbrinolysis or no early revascular-
ization at all, including the aforementioned GUSTO-I
and SHOCK trial scores (7,9). As performance of early
revascularization is known to be the most important
measure to reduce mortality in CS, the use of pre-PCI
trials might induce a certain bias. Furthermore, vari-
ables of the revascularization procedure, which have
been shown to be independently associated with
clinical outcome, such as TIMI ﬂow grade, could not
be taken into account. Other scores are complex and
impracticable in clinical routine, especially in an acute
setting. Notably, most of the scores are not validated.
However, to demonstrate that a proposed prognostic
model is valuable, it is insufﬁcient to prove that it
predicts outcome in the initial development cohort.
Rather, evidence is needed showing that the model
performs well in other patient cohorts too.
The recently published score proposed by Harjola
et al. (10), was developed in the whole CardShock
study population, an unselected cohort of CS patients
with a broad spectrum of etiologies (i.e., not only AMI
related). We developed our score only for patients
with AMI-related CS undergoing PCI, and included
data on TIMI ﬂow after PCI. AMI is by far the leading
cause of CS and is independently associated with
mortality compared to CS without AMI (10). The
CardShock study was chosen for validation of our
score because it is a large, recently published Euro-
pean prospective observational multicenter study on
CS. For validation, however, we selected only pa-
tients with AMI-related CS undergoing primary PCI.
Most of the variables included in our score are well-
known risk factors for worse clinical outcomes of CS
patients. Age, a major independent risk factor, was
consequently included in almost all other proposed
scoring systems for CS (6–10,15). Similarly, renal
insufﬁciency was incorporated in many other scores
(4,7–9). Because GFR might not provide a correct
measure of renal function in the setting of acute renal
failure and because it has been shown that creatinine
has a better predictive value for 1-year mortality
compared to GFR assessed by different equations in a
subanalysis of the IABP-SHOCK II trial (16), we
decided to use creatinine as the measure of renal
function. Given that in most patients (including our
cohort) renal function before the onset of CS was not
recorded, it remains unclear whether it arises from
acute renal failure or whether it is due to a pre-
existing chronic renal insufﬁciency. Most likely, it is
a combination of these 2 situations, which are both
related to an adverse clinical outcome. Lactate
FIGURE 3 Score Validation Analysis
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For validation, Kaplan-Meier analyses for 30-day mortality according to the IABP-SHOCK
II (Intraaortic Balloon Pump in Cardiogenic Shock) score categories were performed for
(A) the validation cohort of the IABP-SHOCK II registry and (B) the external validation
cohort of the CardShock trial. Both analyses show a highly signiﬁcant increase in
mortality rates per the score categories.
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1919concentrations are also known to be strongly and
independently associated with mortality in CS. This
underlined the importance of impaired tissue hypo-
perfusion for clinical outcome.
The association between reduced TIMI ﬂow after
PCI and adverse outcomes is pathophysiologically
plausible and was an independent predictor for
mortality in the study from Garcia-Alvarez et al. as
well as in the large German ALKK (Arbeitsgemein-
schaft Leitende Kardiologische Krankenhausärzte)
registry (6,15). Serum glucose levels have been shown
to be an independent predictor of mortality in AMI
and AMI-related CS, especially in patients without
diabetes mellitus (17,18). However, interestingly,
none of the previously mentioned existing scores
included serum glucose levels. Also, history of stroke
was not included in the previous scores. In contrast to
other studies, previous AMI or CABG as signs for more
severe ischemic heart disease were not predictive in
our analysis. This might be due to the low prevalence
of these conditions in our patients.
The results of our analyses show a stepwise in-
crease in mortality according to the different score
categories, both in the IABP-SHOCK II trial as well
as in the 2 validation cohorts. Furthermore, the
score showed a good performance for prediction of
the risk for short-term mortality in all investigated
cohorts and is well calibrated. CS is known to be
characterized by highly variable mortality rates and
clinical trials on CS are difﬁcult to interpret due to
the highly heterogeneous patient cohorts (3). This
might be 1 explanation for the lack of evidence-
based therapeutic approaches in CS. Categorization
of the patients according to the proposed IABP-
SHOCK II score might help prospectively create
homogenous collectives for future observational
and randomized clinical trials. Beyond this, and
more importantly, the score might serve as a tool
for early clinical risk stratiﬁcation of CS patients,
which can be performed directly after PCI in the
catheterization laboratory. All variables can easily
be assessed and are readily available by point-of-
care testing or immediate blood gas analysis, such
as glucose or blood lactate. We believe that it might
also be helpful for clinical decision making with
respect to the selection of management strategies
(e.g., deciding whether to implant a mechanical
support device). Of course, calculation of a single
score will never be the only variable determining
such a far-reaching decision, which must take into
account many other individual aspects, such as the
patient’s comorbidities and neurological situation.
However, the score might provide valuable assis-
tance for the clinician.STUDY LIMITATIONS. The main limitation of this
study was that with 480 patients in the development
cohort and 137 and 98 patients in the validation
cohorts, the populations were still rather small.
However, it should be emphasized that the IABP-
SHOCK II trial is the largest recent randomized,
controlled clinical trial in the setting of infarct-related
CS and the CardShock study is a large European
prospectively enrolled cohort of patients with CS.
Another limitation was that a certain number of
patients needed to be excluded from the analyses
due to missing data regarding the score variables.
However, event rates were comparable in the
included and excluded sample of patients—both in
the developmental and registry validation cohorts.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
IABP-SHOCK II score, which incorporates age, prior
stroke, admission blood glucose, creatinine and
lactate levels, and impaired post-PCI coronary ﬂow,
can effectively stratify patients with infarct-related CS
for 30-day risk of mortality.
TRANSLATIONAL OUTLOOK: Future studies
should evaluate the utility of this risk score to
guide selection of patients with infarct-related CS
for advanced mechanical circulatory support
modalities.
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1920This ﬁnding precluded a relevant bias of our analysis.
Furthermore, both in IABP-SHOCK II and in Card-
Shock, TIMI ﬂow after PCI was not assessed by a core
laboratory. Available data showed that TIMI ﬂow was
usually classiﬁed higher if it was investigator re-
ported compared to core-lab assessment (19). This
might produce a certain bias with respect to the true
predictive value of a “correctly” assessed TIMI ﬂow.
However, the score will be applied in clinical routine,
where TIMI ﬂow will be assessed by the treating
physician. Therefore, the fact that TIMI ﬂow was
investigator reported is rather an advantage, as it is
closer to the real-life setting.
CONCLUSIONS
The IABP-SHOCK II risk score is a simple tool that can
be rapidly calculated in the catheterization laboratory
setting and applied in clinical routine. It might
therefore serve for identifying patients for future
clinical trials and, more importantly, it might help
stratify patients according to their risk for short-term
mortality and thus facilitate clinical decision making.ADDRESS FOR CORRESPONDENCE: Dr. Janine Pöss,
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